Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

New Data On Novartis' Lucentis Confirms Benefits Of Individualized Treatment

Novartis AG (NVS: Quote) said new data for Lucentis (ranibizumab), the only anti-VEGF therapy licensed across three ocular indications, show that individualized treatment with Lucentis provides sustained improvement in vision with a low number of injections.

In addition, Lucentis exhibited benefits in visual acuity outcomes in patients with visual impairment due to choroidal neovascularization secondary to pathological myopia. At present, Lucentis is not approved to treat this condition. Novartis noted that it will submit for regulatory approval in this indication in the European Union in the third quarter of this year and in Japan by late 2012.

Tim Wright, Global Head of Development, Novartis Pharma, commented, "Lucentis has become the standard of care in wet AMD and has helped to significantly improve vision in a majority of patients with this disease. These new data confirm that an individualized treatment approach can lead to optimal improvements in vision with a low average number of treatments, thus ensuring that patients with retinal diseases are not over- or under-treated. In addition, these data add to the well-characterized safety profile of Lucentis."

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.